Novel compounds that are modulators of PPAR-type receptors having the structural formula (I): are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and in the field of cardiovascular diseases, immune diseases and/or diseases linked to the metabolism of lipids), or, alternatively, into cosmetic compositions.